-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Cartesian Therapeutics, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q3 2022.
- Cartesian Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2022 was -$321K, a 102% decline year-over-year.
- Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$19M, a 3020% decline from 2022.
- Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$609K, a 104% decline from 2021.
- Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $16M.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)